Defymed Inc.
Implantable, bioartificial devices for a range of therapeutic applications
This article was originally published in Start Up
Executive Summary
Defymed Inc.’s MAILPAN (MAcro-encapsulation of PANcreatic Islets) is a bioartificial pancreas that can use a broader pool of cell types while protecting the cells from rejection by the immune system.
You may also be interested in...
Closing In On An Artificial Pancreas
Medtronic may be the front-runner in the race to market, but a number of medtech start-ups hope investors will find merit in their innovative technologies. Profiles of Beta-O2, Defymed, and Pancreum.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.